WO1995028398A1 - Nouvelles formes cristallines de 1-[5-methanesulfonamidoindolyle-2-carbonyle]-4-[3-(1-methylethylamino)-2-pyridinyl]piperazine - Google Patents
Nouvelles formes cristallines de 1-[5-methanesulfonamidoindolyle-2-carbonyle]-4-[3-(1-methylethylamino)-2-pyridinyl]piperazine Download PDFInfo
- Publication number
- WO1995028398A1 WO1995028398A1 PCT/US1995/002166 US9502166W WO9528398A1 WO 1995028398 A1 WO1995028398 A1 WO 1995028398A1 US 9502166 W US9502166 W US 9502166W WO 9528398 A1 WO9528398 A1 WO 9528398A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methanesulfonamidoindolyl
- pyridinyl
- carbonyl
- piperazine
- methylethylamino
- Prior art date
Links
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title abstract description 73
- 239000013078 crystal Substances 0.000 title abstract description 34
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 5
- 238000001228 spectrum Methods 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 abstract description 32
- 150000001875 compounds Chemical class 0.000 abstract description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 238000010992 reflux Methods 0.000 description 21
- 239000000203 mixture Substances 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000002002 slurry Substances 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 239000012458 free base Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 229940098779 methanesulfonic acid Drugs 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 206010001513 AIDS related complex Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropyl acetate Chemical compound CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical compound CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- HYEKZNGYLDKBQG-FYZOBXCZSA-N (6R)-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate Chemical compound O.CC=1CS[C@H]2N(C1C(=O)O)C(C2)=O HYEKZNGYLDKBQG-FYZOBXCZSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 206010020144 Histoplasmosis disseminated Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241001072332 Monia Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Definitions
- US Patent 4,521,431 discloses forms 1 and 2 of ranitidine hydrochloride.
- US Patent 4,504,657 claims "crystalline 7-[D- ⁇ -(p-hydroxyphenyl)acetamido]-
- l-[5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-(l- methylethylamino)-2-pyridinyl]piperazine monomethanesulfonate salt known as the "T" form with a powder X-ray diffraction spectrum of that set forth in the claims.
- DETAILED DESCRIPTION OF THE INVENTION l-[5-Methanesulfonamidoindolyl-2-carbonyl]-4-[3-(l-methylethyl- amino)-2-pyridinyl]- piperazine is known, see International Publication No. WO 91/09849 (EXAMPLE 105).
- piperazine monomethanesulfonate salt is produced by starting with l-[5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-(l- methylethylamino)-2-pyridinyl]piperazine monomethanesulfonate salt in other than the "S" form and dissolving it in a dissolving solvent selected from the group consisting of methanol, ethanol, acetonitrile, dimethyl sulfoxide and dimethylformamide or mixture thereof; it is preferred that the dissolving solvent is methanol.
- methylene chloride can be used as a co-dissolving solvent preferably with methanol, but alone will not appreciably dissolve the starting material.
- a sufficient quantity of crystallizing solvent which is selected from the group consisting of acetone, acetonitrile, isopropanol, n-propanol, methyl t-butyl ether, toluene, ethyl acetate, n-propyl acetate, i-propyl acetate, tetrahydrofuran, toluene or any isomer of xylene, hexane or heptane; it is preferred that the crystallizing solvent be acetone.
- acetone (about 4 ml/g of l-[5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-(l-methylethyl- amino)-2-pyridinyl]piperazine monomethanesulfonate salt) is added over a short period, for example five or ten minutes. At this point it is desirable and preferred to seed the crystallization with a small amount of the "S" crystal form. The mixture is stirred at reflux until crystallization occurs. The mixture can be filtered while hot or cooled.
- the "T" crystal form (also known as form XI) of l-[5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-(l-methylethyl- amino)-2-pyridinyl]piperazine monomethanesulfonate salt is produced by starting with l-[5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-( 1-methylethyl- amino)-2-pyridinyl]piperazine monomethanesulfonate salt in other than the "T" form and recrystallizing from a dissolving solvent (as identified above).
- a crystallizing solvent identified above is optional.
- the "T” form of l-[5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-(l-methylethyl- amino)-2-pyridinyl]p ⁇ perazine monomethanesulfonate salt can be produced from either the free base or a different crystal form of the mesylate salt as is described above for the "S" crystal form.
- human retrovirus indicates human immunodeficiency virus type I, or strains thereof apparent to one skilled in the art, which belong to the same viral families and which create similar physiological effects in humans as various human retroviruses.
- Patients to be treated would include those individuals (1) infected with one or more than one strain of a human retrovirus as determined by the presence of either measurable viral antibody or antigen in the serum and (2) having either a symptomatic AIDS defining infection such as (a) disseminated histoplasmosis, (b) isopsoriasis, (c) bronchial and pulmonary candidiasis including pneumocystic pneu ⁇ monia (d) non-Hodgkin's lymphoma or (e) Kaposi's sarcoma and being less than sixty years old; or having an absolute CD4 lymphocyte count of less than 200/m in the peripheral blood.
- a symptomatic AIDS defining infection such as (a) disseminated histoplasmosis, (b) isopsoriasis, (c) bronchial and pulmonary candidiasis including pneumocystic pneu ⁇ monia (d) non-Hodgkin's lymphoma or (e) Ka
- Suitable dosage forms include tablets, capsules, suspensions, solutions and elixirs.
- An effective amount is from about 0.1 to about 500 mg/kg/day.
- a typical unit dose for a 70 kg human would be from about 10 mg to about 2000 mg, preferably about 100 mg to about 1000 mg taken one to six times per day.
- the exact dosage and frequency of administration depends on whether "S" or the "T” form of l-[5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-(l-methylethyl- amino)-2- pyridinyl]piperazine monomethanesulfonate salt is used, the particular condition being treated, the severity of the condition being treated, the age, weight, general physical condition of the particular patient, other medication the individual may be taking as is well known to those skilled in the art and can be more accurately determined by measuring the blood level or concentration of the l-[5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-(l-methylethyl- amino)-2-pyridinyl]piperazine monomethanesulfonate salt in the patient's blood and/or the patient's response to the particular condition being treated.
- ARC AIDS-related complex
- AIDS patients would typically be treated with higher oral doses (about 1 to about 500 mg/kg/day).
- the ratios of solvents used are volume/volume (v/v).
- the ratio of the solid to the solvent is weight volume (wt/v).
- the mixture is warmed to 40° and isopropanol (325 ml) is added.
- the mixture is held at 37-42° and crystals are observed within 2-3 hours.
- the slurry is cooled over 2 hr to 15° and filtered.
- the cake is washed with isopropanol (100 ml) and methyl-t-butyl ether (250 ml) then dried to give the title compound, mp 221-228°.
- the mixture is concentrated under reduced pressure at 10° to 10 1, diluted with acetonitrile (160 kg) and concentrated to 10 1.
- the residue is then slurried in acetonitrile (240 1), the mixture is heated to 63° and methanesulfonic acid (1.29 kg, 13.4 moles) is added.
- the mixture is heated further to 70-75° and after stirring at that temperature for 4.5 hr it is cooled to 32°.
- the product is collected on a filter, rinsed with acetonitrile (50 1) and dried to give the title compound, mp 222-229°.
- the mixture is heated at reflux until dissolved and then concentrated atmospherically to 150 ml volume.
- the mixture is seeded with 10 mg of previously isolated "T" crystal form and reflux is continued until crystallization is observed.
- the slurry is held at reflux for 16 hr and filtered without cooling and dried to give the title compound.
- the slurry is seeded with 10 mg of previously isolated "T" crystal form. After refluxing for 2-3 hr the slurry is cooled to 15°, filtered, washed with acetone (50 r. and dried to give the title compound, mp 213-228°.
- EXAMPLE 8 "T" Crystal Form Of l-[5-methanesulfonamidoindolyl-2-carbon- yl]-4-[3- (l-methylethylamino)-2-pyridinyl]piperazine monomethanesulfonate salt l-t5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-(l-methylethyl- amino)-2-pyridinyl]- piperazine (free base, THF solvate, 100.0 g, 0.18 moles) is slurried in methanol (250 ml) to which is added methanesulfonic acid (17.65 g, 0.18 moles).
- the mixture is heated at reflux until dissolved and then concentrated atmospherically to about 300 ml volume at which time it is seeded with 10-15 mg of previously isolated l-[5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-( 1-methylethyl- amino)-2-pyridinyl]piperazine monomethanesulfonate salt "T" crystal form.
- the atmospheric concentration is continue to a 200 ml volume. While maintaining reflux, acetone (175 ml) is added over about 10 minutes. The mixture is seeded again with 10-15 mg of previously isolated l-[5-methanesulfonamidoindolyl-2-carb -..
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95911842A EP0755393B1 (fr) | 1994-04-15 | 1995-03-01 | Nouvelles formes cristallines de 1-[5-methanesulfonamidoindolyle-2-carbonyle]-4- 3-(1-methylethylamino)-2-pyridinyl]piperazine |
DE69523447T DE69523447T2 (de) | 1994-04-15 | 1995-03-01 | Kristallformen von 1-[5-methansulfonamidoindolyl-2-carbonyl]-4-[3-[1-methylethylamino]-2-pyridinyl] piperazin |
SI9530556T SI0755393T1 (en) | 1994-04-15 | 1995-03-01 | Novel crystal forms of 1-(5-methanesulfonamidoindolyl-2-carbonyl)-4- 3-(1-methylethylamino)-2-pyridinyl)piperazine |
CA002184598A CA2184598C (fr) | 1994-04-15 | 1995-03-01 | Nouvelles formes cristallines de 1-[5-methanesulfonamidoindolyle-2-carbonyle]-4-[3-(1-methylethylamino)-2-pyridinyl]piperazine |
US08/732,254 US6452007B1 (en) | 1994-04-15 | 1995-03-01 | Crystal forms of 1-[5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-(1-methylethylamino)-2-pyridinyl]piperazine |
DK95911842T DK0755393T3 (da) | 1994-04-15 | 1995-03-01 | Nye krystalformer af 1-[5-methansulfonamidoindolyl-2-carbonyl]-4-[3-(1-methylethylamino)-2-pyridinyl]piperazin |
SK1229-96A SK282424B6 (sk) | 1994-04-15 | 1995-03-01 | "S" a "T" kryštalické formy 1-[5-metánsulfónamidoindolyl-2- karbonyl]-4-[3-(1-metyl-etylamino)-2-pyridinyl] piperazínu |
AU35136/95A AU693939B2 (en) | 1994-04-15 | 1995-03-01 | Novel crystal forms of 1-(5-methanesulfonamidoindolyl-2- carbonyl)-4-(3-(1-methylethylamino)-2-pyridinyl) piperazine |
RU96119978A RU2136677C1 (ru) | 1994-04-15 | 1995-03-01 | Новые кристаллические формы 1-[5-метансульфонамидоиндолил-2-карбонил]-4-[3-(1- метилэтиламино)-2-пиридинил]пиперазина |
NZ282211A NZ282211A (en) | 1994-04-15 | 1995-03-01 | Crystal form of piperazine compound; crystal forms of compound, identified by powder x-ray diffraction (xrd) spectrum |
AT95911842T ATE207481T1 (de) | 1994-04-15 | 1995-03-01 | Kristallformen von 1-(5-methansulfonamidoindolyl- 2-carbonyl)-4-(3-(1-methylethylamino)-2- pyridinyl) piperazin |
MX9604831A MX9604831A (es) | 1994-04-15 | 1995-03-01 | Formas nuevas de cristal de 1-[5-metanosulfonamidoindolil-2-carbonil]-4-[3-(1-metiletila mino)-2-piridinil]-piperazina. |
JP52695295A JP3817261B2 (ja) | 1994-04-15 | 1995-03-01 | 1−[5−メタンスルホンアミドインドリル−2−カルボニル]−4−[3−(1−メチルエチルアミノ)−2−ピリジニル]ピペラジンの新規結晶形 |
HU9602857A HU226827B1 (en) | 1994-04-15 | 1995-03-01 | Novel crystal forms of 1-[5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-(1-methylethylamino)-2-piridinyl]piperazine |
PL95316688A PL180776B1 (pl) | 1994-04-15 | 1995-03-01 | Sole monometanosulfoniany 1-[5-metanosulfonamidoindolilo-2-karbonylo]-4-[3-(1-metyloetyloamino)-2-pirydynylo] piperazyny |
FI964114A FI111364B (fi) | 1994-04-15 | 1996-10-14 | Uusia 1-[5-metaanisulfonamidoindolyyli-2-karbonyyli]-4-[3-(1-metyylietyyliamino)-2-pyridinyyli]piperatsiinin kidemuotoja |
NO964386A NO310024B1 (no) | 1994-04-15 | 1996-10-15 | Nye krystallformer av 1-[5-metansulfonamidoindolyl-2- karbonyl]-4-[3-(1-metyletylamino)-2- pyridinyl]piperazinmonometansulfonatsalt |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22786094A | 1994-04-15 | 1994-04-15 | |
US08/227,860 | 1994-04-15 | ||
US31178094A | 1994-09-23 | 1994-09-23 | |
US08/311,780 | 1994-09-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995028398A1 true WO1995028398A1 (fr) | 1995-10-26 |
Family
ID=26921831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/002166 WO1995028398A1 (fr) | 1994-04-15 | 1995-03-01 | Nouvelles formes cristallines de 1-[5-methanesulfonamidoindolyle-2-carbonyle]-4-[3-(1-methylethylamino)-2-pyridinyl]piperazine |
Country Status (26)
Country | Link |
---|---|
US (1) | US6452007B1 (fr) |
EP (1) | EP0755393B1 (fr) |
JP (1) | JP3817261B2 (fr) |
KR (1) | KR100364941B1 (fr) |
CN (1) | CN1147253A (fr) |
AT (1) | ATE207481T1 (fr) |
AU (1) | AU693939B2 (fr) |
CA (1) | CA2184598C (fr) |
CZ (1) | CZ287164B6 (fr) |
DE (1) | DE69523447T2 (fr) |
DK (1) | DK0755393T3 (fr) |
ES (1) | ES2164147T3 (fr) |
FI (1) | FI111364B (fr) |
HU (1) | HU226827B1 (fr) |
IL (1) | IL113162A (fr) |
LV (1) | LV12957B (fr) |
MX (1) | MX9604831A (fr) |
MY (1) | MY116830A (fr) |
NO (1) | NO310024B1 (fr) |
NZ (1) | NZ282211A (fr) |
PL (1) | PL180776B1 (fr) |
PT (1) | PT755393E (fr) |
RU (1) | RU2136677C1 (fr) |
SK (1) | SK282424B6 (fr) |
TW (1) | TW393478B (fr) |
WO (1) | WO1995028398A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6177101B1 (en) | 1998-06-11 | 2001-01-23 | Pharmacia & Upjohn Company | Delavirdine high strength tablet formulation |
US6872811B1 (en) | 1998-09-30 | 2005-03-29 | Millennium Pharmaceuticals, Inc. | HRPCa9 and HRPCa10 nucleic acids and polypeptides |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102011113749A1 (de) * | 2011-09-14 | 2013-03-14 | Aicuris Gmbh & Co. Kg | Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991009849A1 (fr) * | 1989-12-28 | 1991-07-11 | The Upjohn Company | Composes anti-sida diaromatiques substitues |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3565924A (en) | 1968-07-01 | 1971-02-23 | Wisconsin Alumni Res Found | 25-hydroxycholfcalciferol |
US3833622A (en) | 1969-03-17 | 1974-09-03 | Upjohn Co | Crystalline 25-hydroxycholecalciferol hydrate and structurally related compounds |
GB1532682A (en) | 1976-04-27 | 1978-11-22 | Bristol Myers Co | Process for the preparation of cephadroxil |
IL63968A (en) | 1980-10-01 | 1985-10-31 | Glaxo Group Ltd | Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it |
US5563142A (en) * | 1989-12-28 | 1996-10-08 | The Upjohn Company | Diaromatic substituted compounds as anti-HIV-1 agents |
US5599930A (en) * | 1991-07-03 | 1997-02-04 | The Upjohn Company | Substituted indoles as anti-AIDS pharmaceuticals |
-
1995
- 1995-03-01 NZ NZ282211A patent/NZ282211A/en not_active IP Right Cessation
- 1995-03-01 ES ES95911842T patent/ES2164147T3/es not_active Expired - Lifetime
- 1995-03-01 PL PL95316688A patent/PL180776B1/pl unknown
- 1995-03-01 MX MX9604831A patent/MX9604831A/es unknown
- 1995-03-01 US US08/732,254 patent/US6452007B1/en not_active Expired - Lifetime
- 1995-03-01 JP JP52695295A patent/JP3817261B2/ja not_active Expired - Lifetime
- 1995-03-01 KR KR1019960705760A patent/KR100364941B1/ko not_active IP Right Cessation
- 1995-03-01 AU AU35136/95A patent/AU693939B2/en not_active Expired
- 1995-03-01 WO PCT/US1995/002166 patent/WO1995028398A1/fr active IP Right Grant
- 1995-03-01 RU RU96119978A patent/RU2136677C1/ru active
- 1995-03-01 EP EP95911842A patent/EP0755393B1/fr not_active Expired - Lifetime
- 1995-03-01 DK DK95911842T patent/DK0755393T3/da active
- 1995-03-01 AT AT95911842T patent/ATE207481T1/de active
- 1995-03-01 CA CA002184598A patent/CA2184598C/fr not_active Expired - Lifetime
- 1995-03-01 CN CN95192523A patent/CN1147253A/zh active Pending
- 1995-03-01 PT PT95911842T patent/PT755393E/pt unknown
- 1995-03-01 HU HU9602857A patent/HU226827B1/hu unknown
- 1995-03-01 CZ CZ19962942A patent/CZ287164B6/cs not_active IP Right Cessation
- 1995-03-01 DE DE69523447T patent/DE69523447T2/de not_active Expired - Lifetime
- 1995-03-01 SK SK1229-96A patent/SK282424B6/sk unknown
- 1995-03-17 TW TW084102592A patent/TW393478B/zh not_active IP Right Cessation
- 1995-03-28 IL IL11316295A patent/IL113162A/xx not_active IP Right Cessation
- 1995-03-28 MY MYPI95000766A patent/MY116830A/en unknown
-
1996
- 1996-10-14 FI FI964114A patent/FI111364B/fi not_active IP Right Cessation
- 1996-10-15 NO NO964386A patent/NO310024B1/no not_active IP Right Cessation
-
2002
- 2002-10-24 LV LVP-02-186A patent/LV12957B/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991009849A1 (fr) * | 1989-12-28 | 1991-07-11 | The Upjohn Company | Composes anti-sida diaromatiques substitues |
Non-Patent Citations (1)
Title |
---|
D.L. ROMERO ET AL.: "Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)- carbonyl]-4-[3-[(1-methylethyl)amino]- pyridinyl]piperazine monomethanesulfonate (U-90152S),", JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 10, WASHINGTON US, pages 1505 - 1508 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6177101B1 (en) | 1998-06-11 | 2001-01-23 | Pharmacia & Upjohn Company | Delavirdine high strength tablet formulation |
US6872811B1 (en) | 1998-09-30 | 2005-03-29 | Millennium Pharmaceuticals, Inc. | HRPCa9 and HRPCa10 nucleic acids and polypeptides |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004106326A1 (fr) | Nouveaux polymorphismes du mesylate d'imatinib | |
WO2006024863A1 (fr) | Forme cristalline stable d'imatinib mesylate et son procede de preparation | |
US20040010151A1 (en) | Lansoprazole polymorphs and processes for preparation thereof | |
KR20010074472A (ko) | 신규의 결정질 형태의 항바이러스성 벤즈이미다졸 화합물 | |
US9856270B2 (en) | Dolutegravir salts | |
US20030144517A1 (en) | Chiral fluoroquinolone arginine salt forms | |
AU1641592A (en) | Crystalline tiagabine hydrochloride monohydrate, its preparation and use | |
WO2018109786A1 (fr) | Nouveaux polymorphes et sels de dérivés de carbamoyle pyridone polycycliques | |
AU693939B2 (en) | Novel crystal forms of 1-(5-methanesulfonamidoindolyl-2- carbonyl)-4-(3-(1-methylethylamino)-2-pyridinyl) piperazine | |
CA2403264A1 (fr) | Formes de sels d'arginine de fluoroquinolone chirales | |
JP5847567B2 (ja) | 活性医薬成分の結晶形態 | |
JP3199736B2 (ja) | アミノアルキル置換された2−アミノ−5−メルカプトチアジアゾール、その製造及び使用 | |
WO2018078383A1 (fr) | Composition pharmaceutique comprenant du selexipag amorphe | |
TWI324517B (en) | 4-(4-trans-hydroxycyclohexyl)amino-2-phenyl-7h-pyrrolo[2,3d]pyrimidine hydrogen mesylate and its polymorphic forms | |
WO1997026880A2 (fr) | Utilisation d'une combinaison de delavirdine et d'un ou plusieurs inhibiteurs de protease chez des patients contamines par le vih-1 | |
US7521472B2 (en) | Crystal of two-ring heterocyclic sulfonamide compound | |
JPWO2004020433A1 (ja) | 新規結晶 | |
AU1580492A (en) | Reissert compounds as anti-hiv agents | |
WO2003104211A2 (fr) | Dichlorhydrate cristallin d'acide acetique [2-[4-[(4-chlorophenyl)-phenyl methyl]-1-piperazinyl] ethoxy] |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95192523.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2184598 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 282211 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995911842 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 122996 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08732254 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1996-2942 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 964114 Country of ref document: FI Ref document number: 1019960705760 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV1996-2942 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1995911842 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1996-2942 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995911842 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 964114 Country of ref document: FI |